Johnson & Johnson intends to submit 11 treatments for regulatory approval by 2015, the health care giant told analysts and investors. Among them are Alzheimer's disease medicine bapineuzumab and type 2 diabetes drug canagliflozin. "We are returning to growth, and we expect to outpace market growth," said Sheri McCoy, vice chairwoman and executive-committee member.

Related Summaries